Therapeutic and diagnostic approaches in precision medicine would benefit from characterizing the asymmetry burden in the spatial distribution of tau in patients with AD, as this asymmetry has implications for clinical impairment, caregiver burden, and disease trajectories. The gene discussed is MAPT; the disease is Alzheimer disease.